Deanxit and Rivotril in Tinnitus Patients

Additional Value of Deanxit in Tinnitus Patients Treated With Rivotril

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00841230

Enrollment

Registered

2009-02-11

Start date

2009-02-28

Completion date

2009-07-31

Last updated

2009-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus

Keywords

Tinnitus

Brief summary

The purpose of this study is to investigate whether increased tinnitus reduction can be obtained with Deanxit in patients already receiving Rivotril.

Interventions

DRUGDeanxit

Deanxit 1x/day

DRUGLactose placebo

Lactose used as placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* pure tone, narrow band noise or polyphonic tinnitus * unilateral or bilateral tinnitus * VAS ≥ 4 * cochleair origin tinnitus * tinnitus present 3 months or more * age 18y or more * intake Rivotril 1mg/d * patient 'able to cooperate' * patient able to fill in TQ en VAS * No pontine angle pathology on MRI

Exclusion criteria

* pulsatile tinnitus * pregnancy or breast feeding * contra-indications Deanxit * recovery myocard infarct * conduction disorder His * untreated glaucoma * MAO inhibitors: 15d stop * otosclerosis * middle ear pathologies * Ménière * somatic tinnitus

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale	3 weeks, 6 weeks

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026